Anionic linear polyglycerol derivatives, a method for manufacturing and applications

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention relates to linear, fully synthetic polyglycerol derivatives that are functionalized with negatively charged groups like sulfates, sulfonates, phosphates, and carboxylates. These polymers can be precisely controlled in their chemical structure and are designed to act as potent anticoagulants. They provide an alternative to naturally derived anticoagulants like heparin, offering improved safety, structural homogeneity, and flexibility. Their unique structure enables applications as therapeutic anticoagulants, coatings for medical devices to prevent blood clotting, or as components in protein delivery gels for tissue engineering.

Use CasesContent extracted from patent full text and abstract with AI.

• Therapeutic anticoagulants for preventing or treating venous and arterial thrombosis, pulmonary embolism, and related cardiovascular disorders.
• Use as safer alternatives to heparin in surgeries, post-surgical prophylaxis, and hospital-based anticoagulation therapy.
• Coating or surface modification of medical devices such as catheters, stents, blood bags, and extracorporeal circuits to prevent clot formation and improve blood compatibility.
• Preparation of gels for the encapsulation, storage, and delivery of proteins or growth factors, useful in tissue engineering or regenerative medicine.
• Diagnostic uses, such as in blood collection tubes or blood-based assays where anticoagulation is necessary to improve sample handling and test accuracy.

BenefitsContent extracted from patent full text and abstract with AI.

• Fully synthetic and structurally well-defined, reducing batch-to-batch variability and eliminating risks of animal-derived contaminants (bacteria, viruses, prions, etc.).
• Adjustable anticoagulant activity via precise control of molecular weight and degree of substitution.
• Lower risk of immunogenic reactions (such as heparin-induced thrombocytopenia, HIT) due to customizable chain length and composition.
• Compatible with effective antidotes (protamine or universal heparin binding polymers), increasing therapeutic control and safety in clinical use.
• Good biocompatibility with low cytotoxicity and hemocompatibility, as confirmed in studies.
• Covalent attachment enables stable, customizable anti-thrombotic coatings for a wide range of device surfaces, overcoming problems of leaching or inconsistent activity found with traditional heparin coatings.
• Potential use in controlled delivery systems for proteins or drugs, advancing applications in tissue engineering and regenerative medicine.
• Predictable pharmacokinetics and reliable anticoagulant effect, reducing the need for intensive monitoring and dose adjustments common with heparin therapy.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to a linear polyglycerol compound, comprising a backbone of linearly linked glycerol residues. This compound is characterized in that it carries a plurality of substituents in the nature of covalently bound negatively charged groups chosen from the group consisting of sulfates, sulfonates, phosphates, phosphonates, bisphosphonates and carboxylates, wherein a degree of substitution of the backbone is preferably between 30 and 100 %. A method of manufacturing the compound as well as uses of this compound are also disclosed.